Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven). The allowed claims are based on a three-gene biomarker signature, specifically elevated expression of PTGR1, PTPN14, and ASPH, to identify patients who may benefit from treatment with LP-184.
The company stated that its RADR artificial intelligence platform was instrumental in identifying the biomarker signature used in the patent, supporting a precision medicine approach for LP-184. In its Phase 1a trial, Lantern reported a 45% disease control rate among patients treated at or above the effective therapeutic dose. The company plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184, LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Additionally, Lantern’s multi-agentic AI co-scientist platform, withZeta.ai, is now commercially available as a subscription-based research platform, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
This patent allowance marks a significant step in Lantern’s precision oncology strategy, potentially improving treatment outcomes by targeting therapies to patients most likely to respond. For the industry, it underscores the growing role of AI in identifying biomarkers and advancing personalized cancer treatments. The impact on patients could mean more effective therapies with fewer side effects, as treatment selection becomes more tailored. Investors and stakeholders will watch Lantern’s upcoming Phase 1b/2 studies closely to see if the biomarker-driven approach translates into clinical benefits.
For more information, visit the full press release at https://ibn.fm/LRGUo and Lantern Pharma’s newsroom at https://ibn.fm/LTRN.
